Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases
Journal Title: Journal of Cancer Research & Therapy - Year 2018, Vol 6, Issue 4
Abstract
Background: Colorectal cancer (CRC) is the third cause of cancer in the world and age is a risk factor for this disease. Treatments such as surgical resection and adjuvant chemotherapy have increased the mean survival and the recurrence-free survival. However, the decrease in the frequency and function of effector T cells in addition to the increase in the frequency of myeloid-derived suppressor cells that have been reported in older individuals could contribute to the impaired efficacy in immunity against cancer. We aimed to evaluate if in old patients with CRC, the pre-treatment immunological status was correlated with patients’ outcome. Methods: Patients with CRC (n = 2) were submitted to curative surgical resection or curative surgical resection plus capecitabine/oxaliplatine. Blood was collected for the evaluation of immunological status prior to the treatment and correlated with patients’ outcome. Results: Approximately 20 months after surgery the patients presented with recurrence-free survival. Patient 2 (66-years-old) with CRC and peritoneal metastases presented higher frequency and absolute cell number of myeloid-derived suppressor cells than patient 1 (58-years-old) with CRC. Patient 2 presented a low frequency of effector memory CD8 T cells in addition to high accumulation of effector memory re-expressing CD45RA (CD4 and CD8 T cells). Conclusion: Immunological status was correlated with the disease complexity and our results suggest that removing/reducing myeloid-derived suppressor cells helps in the control of cancer progression. Immunological status is a useful, low invasive tool to identify the disease complexity and the results can be used in the future development of personal treatment according to the immunological status of the patient.
Authors and Affiliations
Valquiria Bueno, Ana L. Mandaliti, Nora M. Forones
High grade endometrial cancer: A prospective cohort study of the outcome of 120 patients after primary surgery
Objective: The purpose of this study was to assess survival and recurrence site and rate in patients with histological high grade endometrial cancer (grade 3 endometrioid and non endometrioid carcinoma) treated with stag...
Carboplatin-gemcitabine in the treatment of elderly patients with non-small cell lung cancer: An outcome analysis
Introduction: To compare a novel carboplatin-gemcitabine (CG) schedule with gemcitabine (G) monochemotherapy in elderly patients with advanced NSCLC. Methods: The records of all the consecutive elderly patients referred...
Newly isolated compounds from West African Sorghum bicolor leaf sheaths Jobelyn® show potential in cancer immunosurveillance
Jobelyn®, a West African pharmaceutical product derived from Sorghum bicolor leaf sheaths has been shown to possess strong anti-tumour and anti-inflammatory properties. This study aims to evaluate the expression of cell...
Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells
Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy. Aberrant promoter DNA methylation can result in the epigenetic silencing of tumor suppress...
The implementation of randomized trials in the treatment of advanced ovarian cancer with HIPEC: waiting for new evidence
Ovarian cancer (OC) is one of the most frequent mortality causes among female neoplasms. A lot of data is available on the efficiency and the relative safety of the different treatments. In the last twenty years the over...